CONTRACT EXTENSION LETTER OF AGREEMENT hereinafter (“Contract Extension”) made effective as of June 1st 2013 (“Contract Extension Effective Date”).Contract Extension Letter of Agreement • July 11th, 2016 • Protagonist Therapeutics, Inc • Pharmaceutical preparations
Contract Extension to the RESEARCH COLLABORATION AND LICENSE AGREEMENT dated as of June 16, 2012 (the “Collaboration Agreement”) by and between
ContractAbandonment Agreement • July 11th, 2016 • Protagonist Therapeutics, Inc • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Agreement on addition of Additional Collaboration Program hereinafter (“AACP”) made effective as of September 16th 2013 (“AACP Effective Date”).Research Collaboration and License Agreement • July 11th, 2016 • Protagonist Therapeutics, Inc • Pharmaceutical preparations
Addition of Additional Collaboration Program to the Research Plan, an integral part of the RESEARCH COLLABORATION AND LICENSE AGREEMENT dated as of June 16, 2012 (the “Collaboration Agreement”) by and between
LEASELease • July 11th, 2016 • Protagonist Therapeutics, Inc • Pharmaceutical preparations
This Lease (this “Lease”) is dated as of September 30, 2013, between BERRUETA FAMILY PARTNERSHIP, a California limited partnership (“Landlord”), and PROTAGONIST THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO LEASELease • July 11th, 2016 • Protagonist Therapeutics, Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is dated as of March 24, 2014 (the “Effective Date”), by and between Berrueta Family Partnership, a California limited partnership (“Landlord”) and Protagonist Therapeutics, Inc., a Delaware corporation (“Tenant”), with reference to the following facts and objectives:
SECOND AMENDMENT TO LEASELease • July 11th, 2016 • Protagonist Therapeutics, Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is dated and effective as of May 4, 2015, by and between Berrueta Family L.P., a California limited partnership (“Landlord”) and Protagonist Therapeutics, Inc., a Delaware corporation (“Tenant”), with reference to the following facts and objectives:
PROTAGONIST THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT July 10, 2015Investor Rights Agreement • July 11th, 2016 • Protagonist Therapeutics, Inc • Pharmaceutical preparations • Delaware
This Second Amended and Restated Investor Rights Agreement (the “Agreement”) is entered into as of this 10th day of July 2015, by and among Protagonist Therapeutics, Inc., a Delaware corporation (the “Company”) and the holders of the Preferred Stock listed on Exhibit A attached hereto (referred to herein as the “Preferred Holders” or the “Investors”).
